Ziv-Aflibercept (Zaltrap) — CPB 0842 | AETNA Coverage Update

Aetna modified CPB 0842 covering ziv-aflibercept (Zaltrap) for colorectal cancer, effective December 10, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its ziv-aflibercept coverage policy under CPB 0842 Aetna system, narrowing the medically necessary indications to advanced or metastatic colorectal cancer (CRC) — including anal adenocarcinoma and appendiceal adenocarcinoma — billed with HCPCS code J9400. The update also clarifies continuation-of-therapy criteria and explicitly labels all other indications as experimental, investigational, or unproven. If your oncology or infusion billing team submits J9400 claims for anything outside CRC with FOLFIRI or irinotecan, expect a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Ziv-Aflibercept (Zaltrap) — CPB 0842
Policy Code	CPB 0842
Change Type	Modified
Effective Date	December 10, 2025
Impact Level	Medium
Specialties Affected	Oncology, Hematology/Oncology, Infusion Therapy, GI Oncology
Key Action	Confirm all J9400 claims carry an approved CRC diagnosis code (C18.x, C19, C20, or C21.x) and a FOLFIRI or irinotecan combination before billing

---

Aetna Ziv-Aflibercept Coverage Criteria and Medical Necessity Requirements 2025

Aetna's ziv-aflibercept coverage policy is narrow by design. The drug has exactly one covered indication: advanced or metastatic colorectal cancer. That umbrella includes anal adenocarcinoma and appendiceal adenocarcinoma — two diagnoses that billing teams sometimes mis-route or overlook.

To meet medical necessity under CPB 0842, the patient must receive ziv-aflibercept in combination with FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) or in combination with irinotecan alone. The regimen requirement is not optional. A claim for J9400 without the supporting combination agents — J9190 for fluorouracil, J0640 or J0641 for leucovorin, and J9206 for irinotecan — creates an audit flag.

This is a tight coverage policy. Aetna is not covering ziv-aflibercept as a single agent, and it is not covering it for any other cancer type. If your practice treats patients with rare appendiceal or anal adenocarcinomas, make sure your ICD-10 coding reflects that specificity. Codes C21.0 through C21.4 for anal/anal canal malignancies and C18.0 through C18.9 for colon malignancies are all supported under this policy.

Prior Authorization and Reimbursement Considerations

CPB 0842 does not spell out a prior authorization pathway in the published criteria — but that does not mean prior auth is waived. Aetna's standard practice for high-cost oncology drugs like ziv-aflibercept requires prior authorization at the plan level. Check the member's specific plan benefits before assuming J9400 will auto-adjudicate.

Ziv-aflibercept billing carries real reimbursement exposure. J9400 is billed per milligram, and typical dosing runs 4 mg/kg IV every two weeks. At that volume, a missed or denied auth hits hard. Confirm medical necessity documentation — including pathology confirming adenocarcinoma histology, staging records, and the treating oncologist's regimen order — is in the file before you submit.

---

Aetna Ziv-Aflibercept Exclusions and Non-Covered Indications

Aetna draws a hard line here. Every indication outside of advanced or metastatic CRC (including anal adenocarcinoma and appendiceal adenocarcinoma) is experimental, investigational, or unproven.

That matters because ziv-aflibercept has been studied in other tumor types — ovarian cancer, non-small cell lung cancer, and others. None of those are covered under this policy. If a provider submits J9400 with a diagnosis outside the CRC spectrum, Aetna will deny the claim on experimental/investigational grounds.

The related policy worth knowing: CPB 0701 covers VEGF inhibitors for ocular indications. Ziv-aflibercept is a VEGF trap, so some teams conflate the two policies. They are separate. CPB 0842 governs oncologic use only.

---

Coverage Indications at a Glance

---

Aetna Ziv-Aflibercept Billing Guidelines and Action Items 2025

The effective date is December 10, 2025. Here is what your billing team should do before and after that date.

Copy Action Items

If you are unsure how this policy applies to your patient mix — especially for rare CRC subtypes or combination regimen variations — talk to your compliance officer before December 10, 2025.

---

CPT, HCPCS, and ICD-10 Codes for Ziv-Aflibercept Under CPB 0842

HCPCS Codes — Covered When Selection Criteria Are Met

Code	Type	Description Copy
J9400	HCPCS	Injection, ziv-aflibercept, 1 mg

HCPCS Codes — Related to CPB 0842 (Supporting Agents and Comparators)

CPT Codes — Chemotherapy Administration (Related to CPB 0842)

These codes cover the administration services associated with ziv-aflibercept infusion. Ziv-aflibercept billing requires both the drug code (J9400) and the appropriate administration code.

Key ICD-10-CM Diagnosis Codes

The full policy maps to 862 ICD-10-CM codes. The core covered diagnoses are below. Confirm the complete list in the policy source for less common CRC subtypes.

---